NVO Novo Nordisk (NVO) Q3 FY25 earnings call
Novo Nordisk delivered solid Q3 FY25 results, driven by strong obesity care sales and a strategic refocus on diabetes and obesity, supported by pipeline acquisitions and a company-wide transformation. Despite competitive pressures and a narrowed full-year outlook, the company is expanding its portfolio and commercial efforts, including direct-to-patient initiatives and preparing for the launch of the Wegovy pill, to address the substantial unmet medical need in its core therapeutic areas.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
NVO operating KPIs by quarter
| KPI | Jun 2025 Q2 FY25 | This call Sep 2025 Q3 FY25 | Change vs prior quarter |
|---|---|---|---|
| Patients Diabetes and obesity | <46MStarting with our focus on purpose and sustainability, we are now serving almost 46 million patients with our diabetes and obesity treatments.Source: earnings call transcript | ~46MWe're now serving around 46 million people living with diabetes and obesity.Source: earnings call transcript | — |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.